# Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy

> **NCT05605301** · PHASE2 · COMPLETED · sponsor: **University of Virginia** · enrollment: 9 (actual)

## Conditions studied

- Epilepsy; Seizure

## Interventions

- **DRUG:** Oral 2-Deoxy-D-Glucose (2DG)

## Key facts

- **NCT ID:** NCT05605301
- **Lead sponsor:** University of Virginia
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-02
- **Primary completion:** 2024-02-05
- **Final completion:** 2024-02-05
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2024-02-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05605301

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05605301, "Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagnosis of Epilepsy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05605301. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*